Reply  by Chow, Theodore & Peterson, Brett J.
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April 7, 2009:1244–7nother, based on a subgroup of 490 patients from the SCD-
eFT (Sudden Cardiac Death in Heart Failure Trial) cohort (2),
hich also concluded that MTWA testing did not predict arrhyth-
ic events or mortality. After reading these reports, how does one
ct when facing a patient who might be a candidate for an ICD
mplantation? Should one go ahead with the ICD implantation or
esort to testing for MTWA? Does MTWA still have some role to
lay? One approach is to wait and comfort ourselves with the
outine pronouncements that more well-designed studies, enroll-
ng larger number of “representative” patients and with longer
ollow-up periods, are in order. In reference to the latter, a long
ollow-up period has its disadvantages, because one should not
xpect a single, initially carried out MTWA test to be predictive of
linical outcomes of patients afflicted by a changing disease state
ver a protracted period of time, and thus periodic MTWA
ssessment (every 6 to 12 months?) might be advisable. Wouldn’t
his be prudent for other tests (e.g., exercise stress testing), and
hus shouldn’t this also apply to MTWA evaluation? This reader
oes not expect any “light in the tunnel” to be forthcoming by
esorting to “more studies” with “larger study cohorts” and has
ut his hopes only in some “tinkering” with the implemented
TWA testing technology. Vast experience indicates that marked
lterations of the morphology, amplitude, and polarity of the T
aves and J-T intervals are commonplace in both normal subjects
nd patients. Some of these changes can be traced to alterations in
eart rate, but most of them remain unexplained and are encoun-
ered in clinically stable individuals. One wonders as to the impact
f such changes on the magnitude of MTWA. The magnitude of
he MTWA (not reported in the study under consideration [1]) is
f significance for both quantitative and qualitative study designs;
fter all, a cut point of 1.9 V is implemented for the
haracterization of a test as positive/negative/indeterminate. It has
een speculated (not shown) that the MTWA magnitude might be
-wave amplitude-dependent (3), and thus it might be of value to
djust the magnitude of the MTWA by the amplitude of the
orresponding T waves used in the measurement/calculation of
TWA. Such a notion might be more applicable to the time-
omain MTWA methodology using a modified moving average
nalysis, but it applies in principle to the spectral analytic method.
n the latter, one should expect that this “indexing” of MTWA
agnitude values should consider the entire J-T interval in some
orm of representation. However, one should attempt to take the
rst step (however crude) of “indexing” the MTWA magnitude
alues by the corresponding T-wave amplitudes. This should be
pplied separately for patients with normal and prolonged QRS
omplexes. In this context, it might be of value to the readership
or Chow et al. to supply us with the quantitative results of the
TWA of their study and evaluate whether adjusting such
TWA values by the corresponding T-wave amplitudes leads to
n MTWA index with worse, the same, or better prognostic power
han they have identified in their study.
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eply
t is true that despite promising early studies, clinical application of
icrovolt T-wave alternans (MTWA) has become less clear, with
oth the MASTER (Microvolt T Wave Alternans Testing for
isk Stratification of Post-Myocardial Infarction Patients) trial (1)
nd the SCD-HeFT (Sudden Cardiac Death in Heart Failure
rial) substudy (2) failing to demonstrate an association of
TWA with their primary end points. The issue is further
uddied by the conflicting results from the ALPHA (T-wave
lternans in patients with heart failure) study (3), in which
TWA predicted arrhythmic mortality in nonischemic cardiomy-
pathy patients. Although the explanation(s) for such divergent
ndings remain speculative, one possibility is that implantable
ardioverter-defibrillator (ICD) shocks, which were used as end
oints in both the MASTER and SCD-HeFT trials, might be a
oor surrogate for arrhythmic mortality due to lack of specificity.
n a recent MTWA meta-analysis, Hohnloser et al. (4) concluded
hat MTWA studies in which ICD penetration was low and that
sed mortality as the primary end point generally show MTWA to
e a powerful predictor of events. The reverse is true for studies
uch as MASTER and SCD-HeFT, in which ICD penetration
as high and which used ICD shock end points.
Where to go from here with respect to MTWA is a matter of
iffering opinion, but for many, enthusiasm has been replaced by
aution. Attempting to improve prediction through refining inter-
retation of the test (e.g., using MTWA magnitude as a contin-
ous rather than dichotomous index of risk, possibly with adjust-
ent for T-wave amplitude) has conceptual appeal but still
equires clinical validation. In the MASTER trial, exploring
ifferent heart rate cut-off thresholds for defining positive and
egative MTWA test results (i.e., onset heart rate and maximum
egative heart rate) did not improve predictive value (5). Retro-
pective analysis of alternans amplitude as a risk index, as suggested
y Dr. Madias, is certainly possible. In principle, additional
efinements could also be made. For example, because MTWA is
eart rate-dependent, overlap of patient daily heart rate with the
nset heart rate for alternans could be a better index of risk than
hether alternans is present at an arbitrary heart rate threshold of
10 beats/min. Whether trigger-substrate type relationships exist
etween MTWA and, for example, ventricular ectopy are largely
nknown. Utility of MTWA as a component within a “suite” of
oninvasive predictors is also under evaluation in other ongoing
tudies.
With respect to the concept of serial MTWA testing raised by
r. Madias, all MASTER patients were in fact required to
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April 7, 2009:1244–7ndergo annual MTWA testing. We previously reported that
nnual concordance between MTWA test results was relatively
ow, and by the end of the study, approximately two-thirds of
atients had tested differently at least once (6). This finding
upports study designs that include periodic MTWA testing
uring follow-up.
At a more conceptual level, it is important to recognize the dif-
erence between “routine” testing for MTWA and whether MTWA
s a biological phenomenon participates in arrhythmia genesis or
usceptibility. The optimist might say that we need to improve our
nderstanding of how and when to test for MTWA through future
esearch rather than reject the entire concept altogether.
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